医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Pharma Sales Forecast to Grow 5% Annually Through to 2020, Industry’s R&D Pipeline Valued at $493bn

2015年06月11日 PM10:00
このエントリーをはてなブックマークに追加


 

LONDON & BOSTON & TOKYO

Life science market intelligence firm, Evaluate Ltd, is launching their annual complimentary industry report, “EvaluatePharma World Preview 2015, Outlook to 2020,” at the annual BIO International Convention in Philadelphia, June 15-18, 2015, Booth #2111.

The report, which sets the industry standard for consensus forecasts for the life science industry, provides an overview of the sector including key trends, patent expiry impact, top products and companies, R&D spend and consensus forecasts to 2020. Complimentary copies of the executive summary will be available in the Evaluate Booth #2111. Follow @evaluatepharma on Twitter or visit www.evaluategroup.com/WP2015 to download the report on release June 16th. For media attending BIO, a press conference will be held on Tuesday, June 16th at 9:15 AM in room 202B at the Pennsylvania Convention Center.

The Evaluate team will also be showcasing some key data sets and analyses within the EvaluatePharma service including:

  • FDA Post-marketing Adverse Events Module (FAERS) fully integrated with EvaluatePharma R&D and commercial intelligence
  • USA Sales Volume and Pricing including cost and volume per patient
  • Japan Sales, Volume and Pricing including reference pricing and PMDA Approvals
  • Brazil Sales, Volume and Pricing and ANVISA approvals
  • Premier of Evaluate’s “Market Movers & Shakers” Newsletter
  • Orphan Drugs and Biosimilar Analyses for clear, concise insights

In attendance will be CEO, Alex Karle; Head of Research, Anthony Raeside; R&D Product Manager, Melanie Newman; EP Vantage Editor, Lisa Urquhart as well as Evaluate’s USA team including CEO Americas, Debbie Paul, and Vice President, Christine Lindgren. Meetings can be scheduled by going to www.evaluate.com or through the BIO Partnering system, or simply stop by the Evaluate Booth #2111.

About Evaluate Ltd

Evaluate is the trusted source for life science market intelligence and analysis with exclusive consensus forecasts to 2020. Our services include EvaluatePharmaEvaluateClinical Trials and EvaluateMedTech. Our award-winning editorial team, EP Vantage, leverages our strategic analysis to cut through the noise, giving you daily opinion and insights. The Evaluate services enable the life science community to make sound business decisions about value and opportunity. For more information please visit www.evaluate.com. On Twitter: @evaluatepharma, @evaluatemedtech, @evaluateJP, @epclinicaltrial, @epvantage.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150611005659/en/

CONTACT

Evaluate and EP Vantage (for general questions)
Christine Lindgren,
+1 617-866-3906
christine.lindgren@evaluategroup.com
or
Chempetitive
Group (for U.S. media)
Rachel Wallace, +1 781-775-3640
rwallace@chempetitive.com
or
Instinctif
Partners (for non-U.S. media)
Gemma Howe, +44 (0) 20 7457 2020
evaluate@instinctif.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Corindus Announces First Commercial Installation of CorPath® GRX System Outside of U.S.
  • Walmart, JD.com, IBM and Tsinghua University Launch a Blockchain Food Safety Alliance in China
  • Bristol-Myers Squibb Granted Exclusive License by Ono Pharmaceutical for Multiple Programs Targeting Immuno-Suppressive Factors in the Tumor Microenvironment
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia